Terminal Complement Inhibitor Eculizumab in Adult Patients with Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial

American Journal of Kidney Diseases

Volumn 68, Issue 1, 2016, Pages 84-93

  Fakhouri, Fadi ^a   Hourmant, Maryvonne ^a   Campistol, Josep M ^b   Cataland, Spero R ^c   Espinosa, Mario ^d   Gaber, A Osama ^e   Menne, Jan ^f   Minetti, Enrico E ^g   Provôt, François ^h   Rondeau, Eric ⁱ   Ruggenenti, Piero ^j   Weekers, Laurent E ^k   Ogawa, Masayo ^l   Bedrosian, Camille L ^l   Legendre, Christophe M ^m  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF BARCELONA   (Spain)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g CAREGGI UNIVERSITY HOSPITAL   (Italy)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^k UNIVERSITY OF LIÈGE   (Belgium)

^l ALEXION PHARMACEUTICALS   (United States)

^m UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

adults; atypical hemolytic uremic syndrome (aHUS); clinical trial; Eculizumab; hematologic normalization; hemoglobin; kidney disease; lactate dehydrogenase (LDH); platelet count; renal function; Soliris; terminal complement inhibitor; thrombotic microangiopathy (TMA); TMA response

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; ECULIZUMAB; HEMOGLOBIN; LACTATE DEHYDROGENASE; LIVER ENZYME; MONOCLONAL ANTIBODY;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DEATH; DRUG CHRONOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPIDEMIC MENINGITIS; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY FUNCTION; KIDNEY PRESERVATION; MALE; MENINGOCOCCEMIA; MIDDLE AGED; MULTICENTER STUDY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PLASMA TRANSFUSION; PLASMAPHERESIS; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; SIDE EFFECT; SINGLE BLIND PROCEDURE; THROMBOCYTE COUNT; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VERY ELDERLY; ADOLESCENT; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CLINICAL TRIAL; PROSPECTIVE STUDY; REMISSION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; YOUNG ADULT;

EID: 84975266700     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2015.12.034     Document Type: Article

References (27)

1. M. Noris, and G. Remuzzi Atypical hemolytic-uremic syndrome N Engl J Med 361 17 2009 1676 1687
2. P.F. Zipfel, S. Heinen, and C. Skerka Thrombotic microangiopathies: new insights and new challenges Curr Opin Nephrol Hypertens 19 4 2010 372 378
3. K. Benz, and K. Amann Thrombotic microangiopathy: new insights Curr Opin Nephrol Hypertens 19 3 2010 242 247
4. M. Noris, J. Caprioli, E. Bresin, and et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype Clin J Am Soc Nephrol 5 10 2010 1844 1859
5. V. Fremeaux-Bacchi, F. Fakhouri, A. Garnier, and et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults Clin J Am Soc Nephrol 8 4 2013 554 562
6. J. Zuber, F. Fakhouri, L.T. Roumenina, and et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies Nat Rev Nephrol 8 11 2012 643 657
7. C. Loirat, M. Noris, and V. Fremeaux-Bacchi Complement and the atypical hemolytic uremic syndrome in children Pediatr Nephrol 23 11 2008 1957 1972
8. C. Licht, F.G. Pluthero, L. Li, and et al. Platelet-associated complement factor H in healthy persons and patients with atypical HUS Blood 114 20 2009 4538 4545
9. J.M. Campistol, M. Arias, G. Ariceta, and et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document Nefrologia 33 1 2013 27 45
10. M. Le Quintrec, J. Zuber, B. Moulin, and et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome Am J Transplant 13 3 2013 663 675
11. R.P. Rother, S.A. Rollins, C.F. Mojcik, and et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria Nat Biotechnol 25 11 2007 1256 1264
12. US Food and Drug Administration. Soliris (eculizumab) [prescribing information]. Cheshire, CT: Alexion Pharmaceuticals, Inc; 2014.
13. European Medicines Agency. Soliris (eculizumab) [summary of product characteristics]. Paris, France; Alexion Europe SAS; 2015.
14. C.M. Legendre, C. Licht, P. Muus, and et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome N Engl J Med 368 23 2013 2169 2181
15. C. Licht, L.A. Greenbaum, P. Muus, and et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies Kidney Int 87 5 2015 1061 1073
16. A.S. Levey, J. Coresh, T. Greene, and et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values Clin Chem 53 4 2007 766 772
17. R. Rabin, and F. de Charro EQ-5D: a measure of health status from the EuroQol Group Ann Med 33 5 2001 337 343
18. K. Webster, D. Cella, and K. Yost The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation Health Qual Life Outcomes 1 2003 79
19. J.E. Ware Jr., and C.D. Sherbourne The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection Med Care 30 6 1992 473 483
20. A.S. Pickard, M.P. Neary, and D. Cella Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer [erratum in: Health Qual Life Outcomes. 2010;8:4] Health Qual Life Outcomes 5 2007 70
21. J.N. George, and C.M. Nester Syndromes of thrombotic microangiopathy N Engl J Med 371 7 2014 654 666
22. P. Coppo, M. Schwarzinger, M. Buffet, and et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA Reference Center experience PLoS One 5 4 2010 e10208
23. S.R. Cataland, and H.M. Wu How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome Blood 123 16 2014 2478 2484
24. European Medicines Agency. Bexsero (meningococcal group B vaccine) [European public assessment report]. Siena, Italy: Novartis; 2013.
25. G.M. Keating Eculizumab: a guide to its use in atypical haemolytic uraemic syndrome Drugs Ther Perspect 30 2014 166 172
26. A. Hill, R.J. Kelly, A.G. Kulasekararaj, and et al. Eculizumab in paroxysmal nocturnal hemoglobinuria (PNH): a report of all 153 patients treated in the UK [abstract 3472] Blood 120 21 2012 3472
27. F. Fakhouri, Y. Delmas, F. Provot, and et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases Am J Kidney Dis 63 1 2014 40 48